Abstract 4367563: Association Between Embolic Protection Device Use and Periprocedural Outcomes in Carotid Artery Stenting

S Santiago Callegari (Vascular Medicine Outcomes Program, New Haven, Connecticut, United States) G Gaelle Romain (Yale School of Medicine, Branford, Connecticut, United States) O Odaly Balasquide-Odeh (VAMOS Lab- Yale, New Haven, Connecticut, United States) C Christiany Tapia (Yale University, East Haven, Connecticut, United States) D Daniel Pinto (Yale University, New Haven, Connecticut, United States) M Mufti Rahman (Yale University, New Haven, Connecticut, United States) A Aseem Vashist (Yale School of Medicine, Branford, Connecticut, United States) K Kim Smolderen (Yale University, New Haven, Connecticut, United States) C Carlos Mena-Hurtado (Department of Cardiovascular Medicine, Yale University, New Haven, CT)

Abstract

Introduction: Carotid artery stenting (CAS) is increasingly used in carotid revascularization. While embolic protection devices (EPDs) are recommended during CAS to reduce the risk of periprocedural stroke and death, their actual benefit remains debated, and their use remains inconsistent in practice. We aimed to assess the association between no EPD use and in-hospital mortality, stroke, and 30-day mortality after CAS. Methods: Patients undergoing CAS between 2015–2019 were abstracted from the Vascular Quality Initiative (VQI) registry linked with Medicare outcomes claims data and stratified by EPD use (no EPD attempted or failed vs. any EPD). Patients undergoing transcarotid artery revascularization were excluded. A 1:1 propensity score matching was performed on 29 preprocedural characteristics to compare groups. Logistic regression assessed the association between EPD use and in-hospital mortality and CAS-related stroke. Kaplan-Meier and Cox proportional hazards models evaluated 30-day mortality by EPD use. Inverse propensity weighting (IPW) was used as a sensitivity analysis. Results: Among 19,451 patients (mean age 67.1±11.7 years; 41.4% female), 2,062 individuals per group were matched (EPD vs. EPD). There was a significant association between no EPD use during CAS and the combined endpoint of in-hospital mortality or stroke (OR 1.50, 95% confidence interval [CI] 1.13–1.98, p=0.005). Individual outcome analysis demonstrated double the odds of in-hospital mortality among those in the no EPD vs. EPD group (OR 2.40, 95% CI 1.50–3.85, p<0.001), but no association with stroke (OR 1.26, 95% CI 0.91–1.75, p=0.160) (Figure 1). For 30-day mortality, the cumulative incidence was significantly higher among patients undergoing CAS without EPD (4.3% vs. 2.0%), with more than double the risk of 30-day mortality (Hazard Ratio: 2.21, 95% CI 1.51–3.24, p<0.001) (Figure 2). Results were consistent in IPW analyses. Conclusion: Not using an EPD during CAS was associated with higher odds of in-hospital mortality or stroke, and a two-fold increase in 30-day mortality risk. As CAS becomes more common, routine EPD use should be emphasized as a quality-of-care benchmark to improve periprocedural outcomes.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (9)

S

Santiago Callegari

Vascular Medicine Outcomes Program, New Haven, Connecticut, United States

G

Gaelle Romain

Yale School of Medicine, Branford, Connecticut, United States

O

Odaly Balasquide-Odeh

VAMOS Lab- Yale, New Haven, Connecticut, United States

C

Christiany Tapia

Yale University, East Haven, Connecticut, United States

D

Daniel Pinto

Yale University, New Haven, Connecticut, United States

M

Mufti Rahman

Yale University, New Haven, Connecticut, United States

A

Aseem Vashist

Yale School of Medicine, Branford, Connecticut, United States

K

Kim Smolderen

Yale University, New Haven, Connecticut, United States

C

Carlos Mena-Hurtado

Department of Cardiovascular Medicine, Yale University, New Haven, CT